Crucell N.V. · Leiden The Netherlands ·(NASDAQ (GM): CRXL)(Euronext Amsterdam: CRXL)
Company Description
View Crucell N.V. Locations On A US Map
This link will open in a new window
This link will open in a new window Crucell wants to play a crucial role in drug development. The biotech firm develops, produces, and markets vaccines and antibodies to prevent and treat infectious diseases. The company currently markets vaccines, based on its PER.C6 technology, to protect against hepatitis A and B, influenza, and typhoid. It also licenses PER.C6 to other companies, including Merck and Sanofi-Aventis , for use in areas where Crucell has chosen not to work. Crucell's pipeline includes vaccine candidates for influenza, malaria, and rabies. The company has also contracted with the National Institutes of Health (NIH) to produce vaccines for the Ebola virus. To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Crucell N.V. Executives
17 executives listed for Crucell N.V.'s Leiden, location.
| Title | Name & Bio | Contact |
| Chairman | Jan Oosterveld | Network |
| President and CEO | Ronald Brus | Network |
| COO | Cees de Jong | Network |
Competition
Competitive Landscape for Crucell N.V.
Demand for biotechnology research in the fields of medicine, agriculture, food, and science is driven by insurers' willingness to pay for new medical treatments, the global need to produce more food for a rapidly expanding population, and scientists' desire to find solutions for complex scientific and medical issues. Funding for biotech research is often provided by venture capital funds hoping to cash in on new products. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential products is so large, small biotechnology companies can co-exist successfully with large ones if they have expertise in a particular line of research. The industry is capital intensive: average annual revenue per worker is more than $350,000. Biotech firms face stiff competition from pharmaceutical and other companies seeking to be first with a new product or discovery. To read the full description, subscribe now.Top Crucell N.V. Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!